Utility of Early Postoperative DWI to Assess the Extent of Resection of Adult-Type World Health Organization Grade 2 and 3 Diffuse Gliomas

References

1. 1.↵
   1. Ostrom QT,
   2. Price M,
   3. Neff C, et al

   . CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2016–2020. Neuro Oncol 2023;25:1–99 pmid:37793125

   PubMed
2. 2.↵
   1. Duffau H

   1. Bauchet L

   . Epidemiology of Low-Grade Gliomas. In: Duffau H, ed. Diffuse Low-Grade Gliomas in Adults: Berlin, Heidelberg: Springer-Verlag; 2017:13–53
3. 3.↵
   1. Munkvold BR,
   2. Solheim O,
   3. Bartek J, et al

   . Variations in the management of diffuse low-grade gliomas: a Scandinavian multicenter study. Neurooncol Pract 2021;8:706–17 doi:10.1093/nop/npab054 pmid:34777840

   CrossRefPubMed
4. 4.↵
   1. Duffau H,
   2. Taillandier L

   . New concepts in the management of diffuse low-grade glioma: proposal of a multistage and individualised therapeutic approach. Neuro Oncol 2015;17:332–42 doi:10.1093/neuonc/nou153 pmid:25087230

   CrossRefPubMed
5. 5.↵
   1. Wessels PH,
   2. Weber WE,
   3. Raven G, et al

   . Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2003;2:395–403 doi:10.1016/S1474-4422(03)00434-4

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Komori T

   . Update of the 2021 WHO Classification of Tumors of the Central Nervous System: adult diffuse gliomas. Brain Tumor Pathol 2023;40:1–3 doi:10.1007/s10014-022-00446-1 pmid:36538117

   CrossRefPubMed
7. 7.↵
   1. Brar K,
   2. Hachem LD,
   3. Badhiwala JH, et al

   . Management of diffuse low-grade glioma: the renaissance of robust evidence. Front Oncol 2020;10:575658 doi:10.3389/fonc.2020.575658 pmid:33117714

   CrossRefPubMed
8. 8.↵
   1. Weller M,
   2. van den Bent M,
   3. Tonn JC, et al

   . European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017;18:315–29 doi:10.1016/S1470-2045(17)30194-8 pmid:28483413

   CrossRefPubMed
9. 9.↵
   1. Scherer M,
   2. Ahmeti H,
   3. Roder C, et al

   . Surgery for diffuse WHO grade II gliomas: volumetric analysis of a multicenter retrospective cohort from the German study group for intraoperative magnetic resonance imaging. Neurosurgery 2019;86:E64–74 doi:10.1093/neuros/nyz397 pmid:31574147

   CrossRefPubMed
10. 10.↵
    1. Molinaro AM,
    2. Hervey-Jumper S,
    3. Morshed RA, et al

    . Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol 2020;6:495–503 doi:10.1001/jamaoncol.2019.6143 pmid:32027343

    CrossRefPubMed
11. 11.↵
    1. Hervey-Jumper SL,
    2. Zhang Y,
    3. Philips JJ, et al

    . Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma. J Clin Oncol 2023;41:2029–42 doi:10.1200/JCO.21.02929 pmid:36599113

    CrossRefPubMed
12. 12.↵
    1. Wijnenga MM,
    2. French PJ,
    3. Dubbink HJ, et al

    . The impact of surgery in molecularly defined low-grade glioma: an integraded clinical, radiological, and molecular analysis. Neuro Oncol 2018;20:103–12 doi:10.1093/neuonc/nox176 pmid:29016833

    CrossRefPubMed
13. 13.↵
    1. Karschnia P,
    2. Vogelbaum MA,
    3. van den Bent M, et al

    . Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer 2021;149:23–33 doi:10.1016/j.ejca.2021.03.002 pmid:33819718

    CrossRefPubMed
14. 14.↵
    1. Ruiz-Garcia H,
    2. Middlebrooks EH,
    3. Trifiletti DM, et al

    . The extent of resection in gliomas-evidence-based recommendations on methodological aspects of research design. World Neurosurg 2022;161:382–95.e3 doi:10.1016/j.wneu.2021.08.140 pmid:35505558

    CrossRefPubMed
15. 15.↵
    1. Vogelbaum MA,
    2. Jost S,
    3. Aghi MK, et al

    . Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgy 2011;70:234–43 doi:10.1227/NEU.0b013e318223f5a7 pmid:21593697

    CrossRefPubMed
16. 16.↵
    1. Wen PY,
    2. van den Bent M,
    3. Youssef G, et al

    . RANO 2.0: update to the Response Assessment in Neuro-Oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 2023;41:5187–99 doi:10.1200/JCO.23.01059 pmid:37774317

    CrossRefPubMed
17. 17.↵
    1. Belhawi SM,
    2. Hoefnagels FW,
    3. Baaijen JC, et al

    . Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancement. Eur Radiol 2011;21:1526–34 doi:10.1007/s00330-011-2081-y pmid:21331595

    CrossRefPubMed
18. 18.↵
    1. Bette S,
    2. Kaesmacher J,
    3. Huber T, et al

    . Value of early postoperative FLAIR volume dynamic in glioma with no or minimal enhancement. World Neurosurg 2016;91:548–59.e1 doi:10.1016/j.wneu.2016.03.034 pmid:27004759

    CrossRefPubMed
19. 19.↵
    1. Coburger J,
    2. Merkel A,
    3. Scherer M, et al

    . Low-grade glioma surgery in intraoperative magnetic resonance imaging: results of a multicenter retrospective assessment of the German study group for intraoperative magnetic resonance imaging. Neurosurgy 2016;78:775–86 doi:10.1227/NEU.0000000000001081 pmid:26516822

    CrossRefPubMed
20. 20.↵
    1. Scherer M,
    2. Jungk C,
    3. Götz M, et al

    . Early postoperative delineation of residual tumor after low-grade glioma resection by probabilistic quantification of diffusion-weighted imaging. J Neurosurgy 2019;130:2016–24 doi:10.3171/2018.2.JNS172951 pmid:30052158

    CrossRefPubMed
21. 21.↵
    1. Smith JS,
    2. Chang EF,
    3. Lamborn KR, et al

    . Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26:1338–45 doi:10.1200/JCO.2007.13.9337 pmid:18323558

    Abstract/FREE Full Text
22. 22.↵
    1. Hilario A,
    2. Ramos A,
    3. Perez-Nuñez A, et al

    . The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol 2012;33:701–07 doi:10.3174/ajnr.A2846 pmid:22207304

    Abstract/FREE Full Text
23. 23.↵
    1. Dhawan S,
    2. Patil CG,
    3. Chen C, et al

    . Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas. Cochrane Database Syst Rev 2020;20:CD009229 2 doi:10.1002/14651858.CD009229.pub3 pmid:3195816

    CrossRefPubMed
24. 24.↵
    1. von Elm E,
    2. Altman DG,
    3. Egger M, et al

    ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344–49 doi:10.1016/j.jclinepi.2007.11.008 pmid:18313558

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Louis DN,
    2. Perry A,
    3. Reifenberger G, et al

    . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

    CrossRefPubMed
26. 26.↵
    1. Louis DN,
    2. Perry A,
    3. Wesseling P, et al

    . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

    CrossRefPubMed
27. 27.↵
    1. Spetzler RF,
    2. Martin NA

    . A proposed grading system for arteriovenous malformations. J Neurosurgy 1986;65:476–83 doi:10.3171/jns.1986.65.4.0476 pmid:3760956

    CrossRefPubMed
28. 28.↵
    1. Purushotham A,
    2. Campbell BC,
    3. Straka M, et al

    . Apparent diffusion coefficient threshold for delineation of ischemic core. Int J Stroke 2013;10:348–53 doi:10.1111/ijs.12068 pmid:23802548

    CrossRefPubMed
29. 29.↵
    1. Warach S,
    2. Gaa J,
    3. Siewert B, et al

    . Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995;37:231–41 doi:10.1002/ana.410370214 pmid:7847864

    CrossRefPubMedWeb of Science
30. 30.↵
    The R CoreTeam. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2022
31. 31.↵
    1. Norton EC,
    2. Dowd BE,
    3. Maciejewski ML

    . Marginal effects: quantifying the effect of changes in risk factors in logistic regression models. JAMA 2019;321:1304–05 doi:10.1001/jama.2019.1954 pmid:30848814

    CrossRefPubMed
32. 32.↵
    1. Shaw EG,
    2. Berkey B,
    3. Coons SW, et al

    . Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 2008;109:835–41 doi:10.3171/JNS/2008/109/11/0835 pmid:18976072

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Ius T,
    2. Isola M,
    3. Budai R, et al

    . Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival: a single-institution experience in 190 patients. J Neurosurg 2012;117:1039–52 doi:10.3171/2012.8.JNS12393 pmid:23039150

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Jakola AS,
    2. Myrmel KS,
    3. Kloster R, et al

    . Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 2012;308:1881–88 doi:10.1001/jama.2012.12807 pmid:23099483

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Elsheikh M,
    2. Bridgman E,
    3. Lavrador JP, et al

    . Association of extent of resection and functional outcomes in diffuse low-grade glioma: systematic review and meta-analysis. J Neurooncol 2022;160:717–24 doi:10.1007/s11060-022-04192-4 pmid:36404358

    CrossRefPubMed
36. 36.↵
    1. Smith JS,
    2. Cha S,
    3. Mayo MC, et al

    . Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg 2005;103:428–38 doi:10.3171/jns.2005.103.3.0428 pmid:16235673

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Chammas M,
    2. Saadeh F,
    3. Maaliki M, et al

    . Therapeutic interventions in adult low-grade gliomas. J Clin Neurol 2019;15:1–8 doi:10.3988/jcn.2019.15.1.1 pmid:30198226

    CrossRefPubMed